Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1,
2, and 9 that is selective over the cathepsins as well as other protease families, displays
good metabolic stability and permeability, oral bioavailability and low cytochrome P450 (CYP)
inhibition. It is under development for the treatment of coronavirus disease-19 (COVID-19)
resulting from infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2),
where there is significant unmet medical need.